In vitro use of a compound for detecting a cell with a disrupted cell membrane, a cell infected with a pathogen, a dying cell or a dead cell or distinguishing between an early stage apoptotic cell and a late stage apoptotic cell, necrotic cell or dead cell, wherein the compound is a polypeptide which comprises: i) an amino acid sequence as provided in any one of SEQ ID NO's 1 to 8; ii) an amino acid sequence which is at least 50% identical to any one or more of SEQ ID NO's 1 to 8 and which is able to detect a cell with a disrupted cell membrane, a cell infected with a pathogen, a dying cell or a dead cell or distinguish between an early stage apoptotic cell and a late stage apoptotic cell, necrotic cell or dead cell; and/or iii) a biologically active, soluble and/or antigenic fragment of i) or ii) and which is able to detect a cell with a disrupted cell membrane, a cell infected with a pathogen, a dying cell or a dead cell or distinguish between an early stage apoptotic cell and a late stage apoptotic cell, necrotic cell or dead cell, or the compound is an antibody or antigenic binding fragment thereof, wherein the antibody is a monoclonal antibody, humanized antibody, single chain antibody, diabody, triabody, or tetrabody, and/or wherein the antibody is 24/04-10B4, 42/04-42D2, 20/05-3A4 or 23/05-4C6, wherein antibodies 24/04-10B4, 42/04-42D2, 20/05-3A4 and 23/05-4C6 are produced by hydridoma cell lines deposited with the European Collection of Cell Cultures (ECACC) 24/04-10B4-24-8, 42/04-42D2-66-4-1, 20/05/3A4-26-16, 23/05-4C6-29-3 on 11 December 2007 under Deposit Reference Numbers 07121101, 07121102, 07121103, and 07121104 respectively, or by higher antibody secreting subclones of the hybridomas (24/04-10B4-24-8-FACS 9-5, 42/04-42D2-66-4-1-Clone 4, 20/05-3A4-26-16-Clone 5, 23/05-4C6-29-3-Clone 5) deposited with the ECACC on 29 April 2008, and designated Accession numbers 08042901, 08042902, 08042903, and 08042904, respectively. the compound is a polypeptide which comprises: i) an amino acid sequence as provided in any one of SEQ ID NO's 1 to 8; ii) an amino acid sequence which is at least 50% identical to any one or more of SEQ ID NO's 1 to 8 and which is able to detect a cell with a disrupted cell membrane, a cell infected with a pathogen, a dying cell or a dead cell or distinguish between an early stage apoptotic cell and a late stage apoptotic cell, necrotic cell or dead cell; and/or iii) a biologically active, soluble and/or antigenic fragment of i) or ii) and which is able to detect a cell with a disrupted cell membrane, a cell infected with a pathogen, a dying cell or a dead cell or distinguish between an early stage apoptotic cell and a late stage apoptotic cell, necrotic cell or dead cell, or i) an amino acid sequence as provided in any one of SEQ ID NO's 1 to 8; ii) an amino acid sequence which is at least 50% identical to any one or more of SEQ ID NO's 1 to 8 and which is able to detect a cell with a disrupted cell membrane, a cell infected with a pathogen, a dying cell or a dead cell or distinguish between an early stage apoptotic cell and a late stage apoptotic cell, necrotic cell or dead cell; and/or iii) a biologically active, soluble and/or antigenic fragment of i) or ii) and which is able to detect a cell with a disrupted cell membrane, a cell infected with a pathogen, a dying cell or a dead cell or distinguish between an early stage apoptotic cell and a late stage apoptotic cell, necrotic cell or dead cell, or the compound is an antibody or antigenic binding fragment thereof, wherein the antibody is a monoclonal antibody, humanized antibody, single chain antibody, diabody, triabody, or tetrabody, and/or wherein the antibody is 24/04-10B4, 42/04-42D2, 20/05-3A4 or 23/05-4C6, wherein antibodies 24/04-10B4, 42/04-42D2, 20/05-3A4 and 23/05-4C6 are produced by hydridoma cell lines deposited with the European Collection of Cell Cultures (ECACC) 24/04-10B4-24-8, 42/04-42D2-66-4-1, 20/05/3A4-26-16, 23/05-4C6-29-3 on 11 December 2007 under Deposit Reference Numbers 07121101, 07121102, 07121103, and 07121104 respectively, or by higher antibody secreting subclones of the hybridomas (24/04-10B4-24-8-FACS 9-5, 42/04-42D2-66-4-1-Clone 4, 20/05-3A4-26-16-Clone 5, 23/05-4C6-29-3-Clone 5) deposited with the ECACC on 29 April 2008, and designated Accession numbers 08042901, 08042902, 08042903, and 08042904, respectively. wherein the antibody is a monoclonal antibody, humanized antibody, single chain antibody, diabody, triabody, or tetrabody, and/or wherein the antibody is 24/04-10B4, 42/04-42D2, 20/05-3A4 or 23/05-4C6, wherein antibodies 24/04-10B4, 42/04-42D2, 20/05-3A4 and 23/05-4C6 are produced by hydridoma cell lines deposited with the European Collection of Cell Cultures (ECACC) 24/04-10B4-24-8, 42/04-42D2-66-4-1, 20/05/3A4-26-16, 23/05-4C6-29-3 on 11 December 2007 under Deposit Reference Numbers 07121101, 07121102, 07121103, and 07121104 respectively, or by higher antibody secreting subclones of the hybridomas (24/04-10B4-24-8-FACS 9-5, 42/04-42D2-66-4-1-Clone 4, 20/05-3A4-26-16-Clone 5, 23/05-4C6-29-3-Clone 5) deposited with the ECACC on 29 April 2008, and designated Accession numbers 08042901, 08042902, 08042903, and 08042904, respectively.